Physician profile
Leora Horn
NPI 1487881041
$97,754.39
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $34K · 2021: $2,740.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $24,384.49 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $18,678.94 | 2019-2020 | |
| Pfizer INC. | $10,577.11 | 2019-2020 | |
| Emd Serono, INC. | $8,625.00 | 2020 | |
| F. Hoffmann-La Roche Ag | $8,523.23 | 2019-2021 | |
| Hoffmann-La Roche Limited | $7,692.96 | 2019 | |
| Incyte Corporation | $4,988.95 | 2019 | |
| Genentech USA, INC. | $4,855.78 | 2020 | |
| Astrazeneca Uk Limited | $3,349.60 | 2019-2021 | |
| Amgen INC. | $3,300.00 | 2020 | |
| Bristol Myers Squibb Company | $2,703.75 | 2019 | |
| Astrazeneca Ab | $51.07 | 2019 | |
| Genentech, INC. | $23.51 | 2019 |
11 companies reported research payments only; those appear in the research section below.
Research and ownership
$7,948.20 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leora Horn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.